论文信息 - Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma - 字舞流文

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma

D. Dingli | A. Dispenzieri | Shaji K. Kumar | M. Gertz | M. Lacy | W. Hogan | S. Hayman | F. Buadi | P. Kapoor | T. Kourelis | W. Gonsalves

[1] J. Eloy,et al. In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2] N. Munshi,et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[3] D. Weisdorf,et al. Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients , 2014, American journal of hematology.

[4] N. Munshi,et al. Management of myeloma-associated renal dysfunction in the era of novel therapies , 2012, Expert review of hematology.

[5] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[6] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[7] T. Mcelwain,et al. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[8] R. Ebert. Medical education in the United States. , 1977, Daedalus.